Ausgabe 5/2013
Inhalt (29 Artikel)
Principles of dose finding studies in cancer: a comparison of trial designs
Thomas Jaki, Sally Clive, Christopher J. Weir
A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis
Samira Sadat Abolmaali, Ali Mohammad Tamaddon, Rassoul Dinarvand
Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel-loaded microsphere with larotaxel-solution
Zhenzhen Liu, Yukun Feng, Lunhui Zhang, Guofei Li, Lulu Geng, Yan Cui, Fei Teng, Xing Tang, Kaishun Bi, Xiaohui Chen
A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
Eiichiro Suzuki, Masafumi Ikeda, Takuji Okusaka, Shoji Nakamori, Shinichi Ohkawa, Tatsuya Nagakawa, Narikazu Boku, Hiroaki Yanagimoto, Tosiya Sato, Junji Furuse
Predictive pharmacokinetic–pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts
Maurizio Rocchetti, Massimiliano Germani, Francesca Del Bene, Italo Poggesi, Paolo Magni, Enrico Pesenti, Giuseppe De Nicolao
Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel
Hao Wu, Min Huang, Mingjie Lu, Wei Zhu, Yongqian Shu, Peng Cao, Ping Liu
A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer
N. Ramnath, S. Daignault-Newton, G. K. Dy, J. R. Muindi, A. Adjei, V. L. Elingrod, G. P. Kalemkerian, K. B. Cease, P. J. Stella, D. E. Brenner, S. Troeschel, C. S. Johnson, D. L. Trump
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer
Rachel M. Layman, Amy S. Ruppert, Melinda Lynn, Ewa Mrozek, Bhuvaneswari Ramaswamy, Maryam B. Lustberg, Robert Wesolowski, Susan Ottman, Sarah Carothers, Anissa Bingman, Raquel Reinbolt, Eric H. Kraut, Charles L. Shapiro
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
Ruth Plummer, Paul Lorigan, Neil Steven, Lucy Scott, Mark R. Middleton, Richard H. Wilson, Evan Mulligan, Nicola Curtin, Diane Wang, Raz Dewji, Antonello Abbattista, Jorge Gallo, Hilary Calvert
Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
Soo Jung Lee, Jong Gwang Kim, Sang-Woo Lee, Yee Soo Chae, Byung Woog Kang, Yoo Jin Lee, Jun Seok Park, Gyu Seog Choi
A preclinical study on the protective effect of melatonin against methotrexate-induced small intestinal damage: effect mediated by attenuation of nitrosative stress, protein tyrosine nitration, and PARP activation
Viswa Kalyan Kolli, Indirani Kanakasabapathy, Minnie Faith, Hemalatha Ramamoorthy, Bina Isaac, Kasthuri Natarajan, Premila Abraham
Physiologically based pharmacokinetic models for everolimus and sorafenib in mice
Dipti K. Pawaskar, Robert M. Straubinger, Gerald J. Fetterly, Bonnie H. Hylander, Elizabeth A. Repasky, Wen W. Ma, William J. Jusko
Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice
Dipti K. Pawaskar, Robert M. Straubinger, Gerald J. Fetterly, Bonnie H. Hylander, Elizabeth A. Repasky, Wen W. Ma, William J. Jusko
Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
Jennifer A. Chan, Robert J. Mayer, Nadine Jackson, Paige Malinowski, Eileen Regan, Matthew H. Kulke
A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors
J. Capdevila, S. Clive, E. Casado, C. Michie, A. Piera, E. Sicart, M. J. Carreras, C. Coronado, C. Kahatt, A. Soto Matos-Pita, C. Fernandez Teruel, M. Siguero, M. Cullell-Young, J. Tabernero
Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1
Jing-Ming Zhai, Xiao-Yu Yin, Ying-Rong Lai, Xun Hou, Jian-Peng Cai, Xiao-Yi Hao, Li-Jian Liang, Long-Juan Zhang
Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis
S. Fushida, J. Kinoshita, M. Kaji, Y. Hirono, F. Goda, Y. Yagi, K. Oyama, Y. Sudo, Y. Watanabe, T. Fujimura
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies
Laura Q. M. Chow, Derek I. Jonker, Grace K. Dy, Garth Nicholas, Catherine Fortin, Daniel Patricia, Alex A. Adjei, Chandra P. Belani, Ashok Gupta, Jong-Soon Park, Steven Zhang, Eric I. Sbar, Scott A. Laurie
Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer
Wan Zhao, Lingmin Hu, Jiali Xu, Hongbing Shen, Zhibin Hu, Hongxia Ma, Yongqian Shu, Yongfeng Shao, Yongmei Yin
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
Maria Serova, Armand de Gramont, Annemilaï Tijeras-Raballand, Célia Dos Santos, Maria Eugenia Riveiro, Khemaies Slimane, Sandrine Faivre, Eric Raymond
Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer
Akira Tsuburaya, Naoki Nagata, Haruhiko Cho, Naoki Hirabayashi, Michiya Kobayashi, Hiroshi Kojima, Yasuhiro Munakata, Ryoji Fukushima, Yoichi Kameda, Tadakazu Shimoda, Koji Oba, Junichi Sakamoto
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
Joseph M. Gozgit, Rachel M. Squillace, Matthew J. Wongchenko, David Miller, Scott Wardwell, Qurish Mohemmad, Narayana I. Narasimhan, Frank Wang, Tim Clackson, Victor M. Rivera
Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
Makoto Sudo, Tan Min Chin, Seiichi Mori, Ngan B. Doan, Jonathan W. Said, Makoto Akashi, H. Phillip Koeffler
Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro
Juan Pablo Rigalli, Tasmin Reuter, Christel Herold-Mende, Gerhard Dyckhoff, Walter Emil Haefeli, Johanna Weiss, Dirk Theile
Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors
M. W. Saif, C. Erlichman, T. Dragovich, D. Mendelson, D. Toft, F. Burrows, C. Storgard, D. Von Hoff
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias
Robert O’Connor, Melissa G. Ooi, Justine Meiller, Jana Jakubikova, Steffen Klippel, Jake Delmore, Paul Richardson, Kenneth Anderson, Martin Clynes, Constantine S. Mitsiades, Peter O’Gorman
A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer
Mayu Yunokawa, Noriyuki Katsumata, Harukaze Yamamoto, Makoto Kodaira, Kan Yonemori, Chikako Shimizu, Masashi Ando, Kenji Tamura, Yasuhiro Fujiwara
Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer
John Rinehart, Susanne Arnold, Goetz Kloecker, Allen Lim, Muhammad-Ali Zaydan, Thomas Baeker, Jewraj G. Maheshwari, Harry Carloss, Stacey Slone, Brent Shelton, Jessica Croley, Elizabeth Kvale, Michael Brooks, Mark Leggas
Dodging a dogma: is treating beyond progression beneficial?
Aung Naing, Razelle Kurzrock